Celltrion Inc (068270):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9825)
◆英語タイトル:Celltrion Inc (068270) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9825
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on research, development and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, psoriatic arthritis and psoriasis. Its pipeline portfolio spans monoclonal antibody biosmilars for the treatment of rheumatoid arthritis; colorectal cancer; large Intestine Cancer and respiratory disease; and antibody biologics for and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer, seasonal influenza antibody; and antibody drug conjugates. Celltrion develops drugs by utilizing its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has operational presence in Korea, Russia, the UK, and the US. Celltrion is headquartered in Incheon city, South Korea.

Celltrion Inc (068270) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celltrion Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Celltrion Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Celltrion Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Celltrion Enters into Co- Development Agreement with Yonsei University 12
Celltrion Enters into Development Agreement with Emory University 13
Nippon Kayaku Enters into Agreement with Celltrion Healthcare 14
Teva Pharma Enters into Distribution Agreement with Celltrion 15
Licensing Agreements 16
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 16
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 17
Equity Offering 19
Celltrion Healthcare Raises USD900.7 Million in IPO 19
Debt Offering 20
Celltrion Pharm Raises USD27.1 Million in Public Offering of 1.5% Bonds Due 2019 20
Celltrion Pharm Raises USD46.3 Million in Public Offering of 1.5% Bonds Due 2020 21
Celltrion Pharm Raises USD9.2 Million in Public Offering of 1.5% Bonds Due 2019 22
Celltrion Pharm Raises USD56.6 Million in Public Offering of 1.5% Bonds Due 2018 23
Celltrion Raises USD300 Million Public Offering of 2.75% Bonds Due 2018 24
Acquisition 25
Temasek Acquires Additional Stake In Celltrion 25
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 26
Celltrion Inc – Key Competitors 28
Celltrion Inc – Key Employees 29
Celltrion Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Legal and Regulatory 31
Sep 18, 2018: Celltrion receives EIR from the FDA 31
Product News 32
05/23/2017: Miraca Life Sciences Again Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra 32
05/18/2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab) 33
02/22/2017: Mundipharma to launch Truxima (rituximab), the first biosimilar monoclonal antibody for the treatment of cancer, in seven European markets 34
02/17/2017: New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA and REMICADE 35
02/17/2017: Celltrion Healthcare Releases Positive Results from Pivotal Study in Crohns Disease 36
Product Approvals 37
May 30, 2018: Celltrion Completes Resubmission for Biosimilar Candidate to FDA for Review 37
Apr 06, 2018: Celltrion Receives CRL from the U.S. FDA for rituximab biosimilar 38
Jun 29, 2017: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan (rituximab) 39
Clinical Trials 40
Dec 11, 2017: Top UK university hospital unveils data that support the use of rapid infusion for Truxima (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma 40
Nov 05, 2017: Celltrion Healthcare Presents Phase III Switching Data Supporting the Long-Term Efficacy and Safety of Truxima (CT-P10, Biosimilar Rituximab) in Rheumatoid Arthritis Patients 41
Oct 29, 2017: One Year Maintenance And Switching Data In Patients With Crohn’s Disease Support The Use Of Inflectra (Infliximab CT-P13) In IBD 42
Jun 14, 2017: Celltrion Healthcare showcases data supporting the efficacy and safety of Truxima (CT-P10, biosimilar rituximab) in advanced follicular lymphoma and rheumatoid arthritis 43
May 12, 2017: Celltrion Healthcare: Lancet Publishes Full Data-Set from Influential NOR-SWITCH Study 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Celltrion Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celltrion Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celltrion Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Celltrion Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Celltrion Enters into Co- Development Agreement with Yonsei University 12
Celltrion Enters into Development Agreement with Emory University 13
Nippon Kayaku Enters into Agreement with Celltrion Healthcare 14
Teva Pharma Enters into Distribution Agreement with Celltrion 15
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 16
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 17
Celltrion Healthcare Raises USD900.7 Million in IPO 19
Celltrion Pharm Raises USD27.1 Million in Public Offering of 1.5% Bonds Due 2019 20
Celltrion Pharm Raises USD46.3 Million in Public Offering of 1.5% Bonds Due 2020 21
Celltrion Pharm Raises USD9.2 Million in Public Offering of 1.5% Bonds Due 2019 22
Celltrion Pharm Raises USD56.6 Million in Public Offering of 1.5% Bonds Due 2018 23
Celltrion Raises USD300 Million Public Offering of 2.75% Bonds Due 2018 24
Temasek Acquires Additional Stake In Celltrion 25
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 26
Celltrion Inc, Key Competitors 28
Celltrion Inc, Key Employees 29
Celltrion Inc, Subsidiaries 30

List of Figures
Celltrion Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celltrion Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Celltrion Inc (068270):製薬・医療:M&Aディール及び事業提携情報(Celltrion Inc (068270) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆